News
4d
GlobalData on MSNExact Sciences expands partnership with Humana to improve colorectal cancer screeningThe Cologuard Plus test is being offered as an in-network service to eligible Humana Medicare Advantage members.
Easy at-home tests for colon cancer, including FIT and Cologuard, offer alternatives to traditional colonoscopies for early ...
5don MSN
Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...
Unlock URL Order Reprints Gift this Article An image from Cologuard's television ad By Teddy Nykiel – Reporter, Milwaukee Business Journal Mar 2, 2022 Updated Mar 3, 2022 10:26am CST ...
Here, two gastroenterologists share their thoughts on Cologuard: Harish Gagneja, MD, gastroenterologist at Austin (Texas) Gastroenterology: I don’t recommend Cologuard as a first-line test because: ...
A 2013 trial of the first iteration of Cologuard, known as DeeP-C, showed the test is 92% sensitive and 87% specific. Put differently, Cologuard returned false positive results 13% of the time in ...
A decade ago, Exact Sciences launched Cologuard, impacting the fight against colorectal cancer. Its growth of 7000% is in part due to a focus on consumerization.
Cologuard is easy for patients to use and easy for doctors to interpret the results, said Dr. Casey Allen, a surgical oncologist at Allegheny Health Network in Pennsylvania.
The Forbes article also states Cologuard has an 8 percent false-negative rate and a 13 percent false-positive rate Becker’s ASC Review asked three gastroenterologists for their thoughts on Cologuard.
Outside of those patients, Cologuard will own its addressable market and be rapidly adopted by physicians. Eventual penetration into the 70% range of this market is reasonable, and even at $300 ...
The Cologuard can say that you have an abnormality when a colonoscopy would indicate normal. For 45% of people with a positive Cologuard test, no abnormalities will be found upon colonoscopy.
Cologuard measures DNA methylation in two genes: NDRG4 and BMP3. Abnormal methylation of NDRG4 and BMP3, considered tumor suppressors, has been linked to colorectal tumors.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results